Learn more about UC TechAlerts – Subscribe to categories and get notified of new UC technologies

Browse Category: Medical > Therapeutics

Categories

[Search within category]

Antiviral Compounds for HIV and Other Viral Infections

This invention identifies a novel class of HIV inhibitors targeting RNA-protein interactions.

RNA-Based Therapeutic For Mutant KRAS Driven Cancers

Mutations in the KRAS oncogene are found in approximately 20% of human cancers and is the most commonly mutated gene in the RAS family of oncogenes (85% of RAS mutations are KRAS mutations). Moreover, activating KRAS mutations are the major driver mutations in non-small cell lung cancer (NSCLC) with mutations in KRAS accounting for about 30% of NSCLC cases. KRAS mutations are also frequently identified in 40-50% of colorectal cancers (CRC). Despite a long history of research efforts, no targeted therapy is yet available clinically for KRAS mutated cancers.

Chemical Synthesis of Lipid Mediator 22-HDoHE and Structural Analogs

Researchers at the University of California, Davis have developed an efficient method to chemically synthesize the endogenous lipid mediator, 22-hydroxydocosahexaenoic acid (22-HDoHE) which can be applied to related natural mediators and analogs.

Rapid Screening and Identification of Antigenic Components in Tissues and Organs

Researchers at the University of California, Davis have developed an approach to rapidly screen and identify antigenic components in tissues and organs.

Antibodies for Pseudomonas (P.) aeruginosa

Researchers at the University of California, Davis have developed recombinant antibodies (VHH or nanobodies) to diagnose and treat Pseudomonas (P.) aeruginosa infection.

Extracellular Nano-vesicles For Applications In Therapeutic Delivery

Drug delivery relies on nano-sized carriers whose objectives are to protect cargo from the body and to release the cargo at the appropriate site without inducing immunogenic response. The inventors at UCI have developed a method of mass producing extracellular nano-vesicles that have shown promise for drug delivery, but have been slow to progress to clinical trials due to low production yields.

Modulation Of p53 as a Cancer Therapeutic Target

Researchers at the University of California, Davis have designed peptides and oligonucleotide sequences to enhance p53 expression.

Peripheral Nerve Repair By Peptide Amphiphile Nanofibers.

UCLA researchers in the Department of Surgery have developed a novel method that promotes directed nerve growth and peripheral nerve regeneration using peptide amphiphile (PA) nanofibers. The combination of conduit and PA nanofiber scaffold offers greater success than currently used methods of bridging with empty conduits. This novel approach may become a substitute for nerve graft for clinical use in the treatment of peripheral nerve injuries.

Developing Physics-Based High-Resolution Head And Neck Biomechanical Models

UCLA researchers in the Department of Radiation Oncology at the David Geffen School of Medicine have developed a new computational method to model head and neck movements during medical imaging/treatment procedures.

Anti-Androgens for the Treatment of Chemotherapy Resistant Prostate Cancers

Researchers at the University of California, Davis have discovered a special class of androgen inhibitors for the treatment of chemotherapeutic prostate resistant cancers.

Determination Of Absolute Configuration Of Secondary Alcohols Using A Competing Enantioselective Conversion Kit

The absolute configuration of an organic compound dictates its interactions with other chemicals. The Competing Enantioselective Conversion (CEC) method is an attractive method for determining the absolute configuration of secondary alcohols, but the preparation of stock reagent solutions takes longer than the analysis time itself – a mere 1-2 hours. The inventors at UCI have developed a CEC kit which contains stock solutions of the components required for CEC that remain stable and usable for several months.

Microfluidics Device For Digestion Of Tissues Into Cellular Suspension

A microfluidic device that separates single cells from whole tissue in a rapid and gentle manner using hydrodynamic fluid flow. The separated single cell suspensions can then be used in tissue engineering applications, regenerative medicine and the study of cancer.

Sleep Apnea Device with ball valve design

The invention is a compact nasal device for people suffering from sleep apnea, snoring, and other sleep disorders. The invention secures the flow of air through the patients’ nasal passage without the need for uncomfortable bulky masks or bedside devices, making it a convenient and sustainable treatment method.

NOVEL SMALL MOLECULE COMPOUNDS AND TARGET FOR TREATMENT OF AIRWAY HYPERRESPONSIVENESS IN ASTHMA

Novel small molecule compounds that modulate a new target for the treatment of asthma. 

Preparation Of Functional Homocysteine Residues In Polypeptides And Peptides

UCLA researchers in the Department of Bioengineering and Department of Chemistry & Biochemistry have developed a novel method for efficient, chemoselective transformation of methionines in peptides and polypeptides into stable, functional homocysteine derivatives. This method provides a means of creation of new functional biopolymers, site-specific peptide tagging, and synthesis of biomimetic and structural analogs of peptides.

Lipid(S) Conjugated Anticancer Smac Derivatives

UCLA researchers in the Department of Medicine have synthesized monomeric and dimeric second mitochondria derived activator of caspases (SMAC) analogs that can be used for anticancer therapeutics.

Novel Small Protein Inhibitors for Rapid and Controllable CRISPR-Cas9 Interference

This invention identifies a novel class of natural protein-based inhibitors of CRISPR-Cas9, which could eliminate off-target effects of Cas9-mediated gene editing. It also presents an attractive antibiotic strategy and a potential biodefense agent against CRISPR bioterror threat.

Update To Degradable Trehalose Glycopolymers

UCLA researchers in the Department of Chemistry & Biochemistry have designed an improved version of trehalose-based glycopolymer as a degradable alternative to PEG for the purpose of stabilizing a protein during storage and transport.

PAC1 Receptor Agonists for Treatment of Obesity, Diabetes, and Fatty Liver Disease

UCLA researchers have developed novel PAC1 receptor agonists (MAXCAPs) that specifically bind and activate PAC1 receptors to induce satiety and treat multiple metabolic diseases.

Intracellular-Ligand-Responsive Cytotoxic Molecules For Selective T-Cell Mediated Cell Killing

UCLA researchers in the Department of Chemical and Biomolecular Engineering have developed a novel immunotherapeutic strategy that uses a selectively-activated cytotoxic molecule to enable tumor-specific T cell-mediated killing.

Transforming Growth Factor-Beta (TGF-β)-Responsive Single-Chain Variable Fragments And Chimeric Antigen Receptors

UCLA researchers in the Department of Chemical and Biomolecular Engineering have developed chimeric antigen receptors that are responsive to human and mouse TGF-β (Transforming Growth Factor-Beta).

Small Molecule Inhibitors of Cardiovascular and Renal Ectopic Calcification

UCLA researchers in the Department of Medicine have discovered that administration of small molecule inhibitors of ENPP1 or functional antagonists of PPi can substantially attenuate ectopic calcification. This suggests that ENPP1 and PPi can be potential pharmacological targets when developing therapeutics for pathological ectopic calcification.

Methods For The Identification And Targeting Of Brain Regions And Structures

A UCLA physician has developed a method to identify regions of the brain using Diffusion Tensor Imaging MRI to locate afferent and efferent neural tracts that lead to and from the specific region of interest. This technique will improve the accuracy and safety of brain treatments, such as electrical brain stimulation and ultrasound imaging.

Apoe4-Targeted Theraputics That Increase Sirt1

UCLA researchers have identified Alaproclate (A03) as a promising drug candidate to treat Mild Cognition Impairment (MCI) and Alzheimer’s disease (AD) through inhibition of the ApoE4 neurotoxicity.

Combination Of Approved Alzheimer's Drugs With Metabolic Enhancement For Neurodegeneration (MEND) To Comprise A Therapeutic System

UCLA researchers in the Department of Neurology have developed a novel therapeutic program for Alzheimer’s disease, based on the combination of existing AD drugs and a program to enhance metabolic activity.

  • Go to Page: